Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease
John W. Eikelboom, Deepak L. Bhatt, Keith A.A. Fox, Jackie Bosch, Stuart J. Connolly, Sonia S. Anand, Álvaro Avezum, Scott D. Berkowitz, Kelley R. Branch, Gilles R. Dagenais, Camilo Félix, Tomasz J. Guzik, Robert G. Hart, Aldo P. Maggioni, Eva Muehlhofer, Mukul Sharma, Olga Shestakovska, Salim Yusuf
Topics & Concepts
MedicineAspirinHazard ratioInternal medicineCoronary artery diseaseKidney diseaseStroke (engine)CardiologyHeart failureDiabetes mellitusRivaroxabanConfidence intervalWarfarinSurgeryAtrial fibrillationEndocrinologyMechanical engineeringEngineeringPeripheral Artery Disease ManagementAntiplatelet Therapy and Cardiovascular DiseasesAtrial Fibrillation Management and Outcomes